Mast cells in the autonomic nervous system and potential role in disorders with dysautonomia and neuroinflammation.
Theoharides, Theoharis C, Twahir, Assma, Kempuraj, Duraisamy · Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology · 2024 · DOI
Quick Summary
This study examines mast cells, which are immune cells found throughout the body, and how they may be involved in conditions like ME/CFS that affect the nervous system and cause abnormal heart rate and blood pressure responses. Mast cells sit near nerve endings and important organs, where they can release chemicals that affect how the body regulates basic functions like temperature and blood pressure. The researchers suggest that controlling mast cell activation might help treat these conditions, though currently there are no proven treatments.
Why It Matters
This study is important because it proposes a biological mechanism that could unite ME/CFS symptoms (dysautonomia, neuroinflammation, post-exertional malaise) under a mast cell dysfunction hypothesis. If mast cells are indeed central to ME/CFS pathophysiology, it could open new avenues for targeted treatments beyond symptom management. Understanding this connection may also help explain why ME/CFS often co-occurs with other conditions sharing autonomic dysfunction.
Observed Findings
Mast cells are anatomically positioned perivascularly near critical autonomic nervous system structures including the carotid bodies, hypothalamus, adrenal gland, and pineal gland.
Mast cells respond to multiple stimuli beyond allergens, including autonomic nervous system signals, releasing neurosensitizing, proinflammatory, and vasoactive mediators.
Mast cell activation is potentially associated with dysautonomic conditions including POTS, ME/CFS, autism spectrum disorder, and Long-COVID.
There is currently no effective curative treatment for any of these conditions; management focuses on symptom minimization.
Inferred Conclusions
Mast cells may play a central regulatory role in homeostatic functions that are dysfunctional across multiple dysautonomic and neuroinflammatory conditions.
Developing methods to inhibit mast cell stimulation and mediator release relevant to autonomic function could represent a therapeutic strategy for these disorders.
The anatomical proximity of mast cells to autonomic structures suggests a bidirectional communication pathway between immune activation and dysautonomia.
Remaining Questions
Which specific mast cell mediators drive dysautonomic symptoms versus neuroinflammatory symptoms in ME/CFS patients?
What are the primary triggers for pathological mast cell activation in ME/CFS—are they immune, neurological, or autonomic in origin?
What This Study Does Not Prove
This review does not provide direct experimental evidence that mast cells cause ME/CFS or prove causation rather than correlation. It does not demonstrate that mast cell inhibition would be effective or safe in ME/CFS patients, nor does it establish which specific mast cell mediators are responsible for particular ME/CFS symptoms. The study is theoretical and based on existing literature rather than new patient data.